226 related articles for article (PubMed ID: 30777875)
1. A Phase II Study of Alisertib in Children with Recurrent/Refractory Solid Tumors or Leukemia: Children's Oncology Group Phase I and Pilot Consortium (ADVL0921).
Mossé YP; Fox E; Teachey DT; Reid JM; Safgren SL; Carol H; Lock RB; Houghton PJ; Smith MA; Hall D; Barkauskas DA; Krailo M; Voss SD; Berg SL; Blaney SM; Weigel BJ
Clin Cancer Res; 2019 Jun; 25(11):3229-3238. PubMed ID: 30777875
[TBL] [Abstract][Full Text] [Related]
2. Phase II study of alisertib, a selective Aurora A kinase inhibitor, in relapsed and refractory aggressive B- and T-cell non-Hodgkin lymphomas.
Friedberg JW; Mahadevan D; Cebula E; Persky D; Lossos I; Agarwal AB; Jung J; Burack R; Zhou X; Leonard EJ; Fingert H; Danaee H; Bernstein SH
J Clin Oncol; 2014 Jan; 32(1):44-50. PubMed ID: 24043741
[TBL] [Abstract][Full Text] [Related]
3. Preclinical pharmacokinetic/pharmacodynamic/efficacy relationships for alisertib, an investigational small-molecule inhibitor of Aurora A kinase.
Palani S; Patel M; Huck J; Zhang M; Balani SK; Yang J; Chen S; Mettetal J; Manfredi M; Shyu WC; Ecsedy JA; Chakravarty A
Cancer Chemother Pharmacol; 2013 Dec; 72(6):1255-64. PubMed ID: 24101146
[TBL] [Abstract][Full Text] [Related]
4. Population Pharmacokinetics and Exposure-Safety Relationships of Alisertib in Children and Adolescents With Advanced Malignancies.
Zhou X; Mould DR; Yuan Y; Fox E; Greengard E; Faller DV; Venkatakrishnan K
J Clin Pharmacol; 2022 Feb; 62(2):206-219. PubMed ID: 34435684
[TBL] [Abstract][Full Text] [Related]
5. Phase I Study of the Aurora A Kinase Inhibitor Alisertib in Combination With Irinotecan and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma: A NANT (New Approaches to Neuroblastoma Therapy) Trial.
DuBois SG; Marachelian A; Fox E; Kudgus RA; Reid JM; Groshen S; Malvar J; Bagatell R; Wagner L; Maris JM; Hawkins R; Courtier J; Lai H; Goodarzian F; Shimada H; Czarnecki S; Tsao-Wei D; Matthay KK; Mosse YP
J Clin Oncol; 2016 Apr; 34(12):1368-75. PubMed ID: 26884555
[TBL] [Abstract][Full Text] [Related]
6. Pediatric phase I trial and pharmacokinetic study of MLN8237, an investigational oral selective small-molecule inhibitor of Aurora kinase A: a Children's Oncology Group Phase I Consortium study.
Mossé YP; Lipsitz E; Fox E; Teachey DT; Maris JM; Weigel B; Adamson PC; Ingle MA; Ahern CH; Blaney SM
Clin Cancer Res; 2012 Nov; 18(21):6058-64. PubMed ID: 22988055
[TBL] [Abstract][Full Text] [Related]
7. Phase 1 study of the investigational Aurora A kinase inhibitor alisertib (MLN8237) in East Asian cancer patients: pharmacokinetics and recommended phase 2 dose.
Venkatakrishnan K; Kim TM; Lin CC; Thye LS; Chng WJ; Ma B; Chen MH; Zhou X; Liu H; Kelly V; Kim WS
Invest New Drugs; 2015 Aug; 33(4):942-53. PubMed ID: 26084989
[TBL] [Abstract][Full Text] [Related]
8. Investigational Aurora A kinase inhibitor alisertib (MLN8237) as an enteric-coated tablet formulation in non-hematologic malignancies: phase 1 dose-escalation study.
Falchook G; Kurzrock R; Gouw L; Hong D; McGregor KA; Zhou X; Shi H; Fingert H; Sharma S
Invest New Drugs; 2014 Dec; 32(6):1181-7. PubMed ID: 24879333
[TBL] [Abstract][Full Text] [Related]
9. Dose selection for the investigational anticancer agent alisertib (MLN8237): Pharmacokinetics, pharmacodynamics, and exposure-safety relationships.
Venkatakrishnan K; Zhou X; Ecsedy J; Mould DR; Liu H; Danaee H; Fingert H; Kleinfield R; Milton A
J Clin Pharmacol; 2015 Mar; 55(3):336-47. PubMed ID: 25302940
[TBL] [Abstract][Full Text] [Related]
10. Phase I study of MLN8237--investigational Aurora A kinase inhibitor--in relapsed/refractory multiple myeloma, non-Hodgkin lymphoma and chronic lymphocytic leukemia.
Kelly KR; Shea TC; Goy A; Berdeja JG; Reeder CB; McDonagh KT; Zhou X; Danaee H; Liu H; Ecsedy JA; Niu H; Benaim E; Iyer SP
Invest New Drugs; 2014 Jun; 32(3):489-99. PubMed ID: 24352795
[TBL] [Abstract][Full Text] [Related]
11. Preclinical and Dose-Finding Phase I Trial Results of Combined Treatment with a TORC1/2 Inhibitor (TAK-228) and Aurora A Kinase Inhibitor (Alisertib) in Solid Tumors.
Davis SL; Ionkina AA; Bagby SM; Orth JD; Gittleman B; Marcus JM; Lam ET; Corr BR; O'Bryant CL; Glode AE; Tan AC; Kim J; Tentler JJ; Capasso A; Lopez KL; Gustafson DL; Messersmith WA; Leong S; Eckhardt SG; Pitts TM; Diamond JR
Clin Cancer Res; 2020 Sep; 26(17):4633-4642. PubMed ID: 32414750
[TBL] [Abstract][Full Text] [Related]
12. Phase I pharmacokinetic/pharmacodynamic study of MLN8237, an investigational, oral, selective aurora a kinase inhibitor, in patients with advanced solid tumors.
Cervantes A; Elez E; Roda D; Ecsedy J; Macarulla T; Venkatakrishnan K; Roselló S; Andreu J; Jung J; Sanchis-Garcia JM; Piera A; Blasco I; Maños L; Pérez-Fidalgo JA; Fingert H; Baselga J; Tabernero J
Clin Cancer Res; 2012 Sep; 18(17):4764-74. PubMed ID: 22753585
[TBL] [Abstract][Full Text] [Related]
13. Phase I study of the aurora A kinase inhibitor alisertib with induction chemotherapy in patients with acute myeloid leukemia.
Fathi AT; Wander SA; Blonquist TM; Brunner AM; Amrein PC; Supko J; Hermance NM; Manning AL; Sadrzadeh H; Ballen KK; Attar EC; Graubert TA; Hobbs G; Joseph C; Perry AM; Burke M; Silver R; Foster J; Bergeron M; Ramos AY; Som TT; Fishman KM; McGregor KL; Connolly C; Neuberg DS; Chen YB
Haematologica; 2017 Apr; 102(4):719-727. PubMed ID: 28034990
[TBL] [Abstract][Full Text] [Related]
14. Effect of Food on the Pharmacokinetics of the Investigational Aurora A Kinase Inhibitor Alisertib (MLN8237) in Patients with Advanced Solid Tumors.
Falchook GS; Zhou X; Venkatakrishnan K; Kurzrock R; Mahalingam D; Goldman JW; Jung J; Ullmann CD; Milch C; Rosen LS; Sarantopoulos J
Drugs R D; 2016 Mar; 16(1):45-52. PubMed ID: 26689566
[TBL] [Abstract][Full Text] [Related]
15. Relative bioavailability of a prototype oral solution of the Aurora A kinase inhibitor alisertib (MLN8237) in patients with advanced solid tumors.
Falchook GS; Venkatakrishnan K; Sarantopoulos J; Kurzrock R; Mita AC; Fu S; Mita MM; Zhou X; Jung JA; Ullmann CD; Milch C; Rosen LS
Int J Clin Pharmacol Ther; 2015 Jul; 53(7):563-72. PubMed ID: 26073352
[TBL] [Abstract][Full Text] [Related]
16. Phase II Trial of Alisertib in Combination with Irinotecan and Temozolomide for Patients with Relapsed or Refractory Neuroblastoma.
DuBois SG; Mosse YP; Fox E; Kudgus RA; Reid JM; McGovern R; Groshen S; Bagatell R; Maris JM; Twist CJ; Goldsmith K; Granger MM; Weiss B; Park JR; Macy ME; Cohn SL; Yanik G; Wagner LM; Hawkins R; Courtier J; Lai H; Goodarzian F; Shimada H; Boucher N; Czarnecki S; Luo C; Tsao-Wei D; Matthay KK; Marachelian A
Clin Cancer Res; 2018 Dec; 24(24):6142-6149. PubMed ID: 30093449
[TBL] [Abstract][Full Text] [Related]
17. A phase 2 trial of alisertib in patients with relapsed or refractory B-cellnon-Hodgkin lymphoma.
Cohen JB; Maddocks KJ; Huang Y; Christian BA; Jaglowski SM; Flowers CR; Blum KA
Leuk Lymphoma; 2017 Sep; 58(9):1-2. PubMed ID: 28278718
[No Abstract] [Full Text] [Related]
18. Preclinical drug metabolism and pharmacokinetics, and prediction of human pharmacokinetics and efficacious dose of the investigational Aurora A kinase inhibitor alisertib (MLN8237).
Yang JJ; Li Y; Chakravarty A; Lu C; Xia CQ; Chen S; Pusalkar S; Zhang M; Ecsedy J; Manfredi MG; Wu JT; Shyu WC; Balani SK
Drug Metab Lett; 2014 Jul; 7(2):96-104. PubMed ID: 24484538
[TBL] [Abstract][Full Text] [Related]
19. Open-label, multicenter, phase 1 study of alisertib (MLN8237), an aurora A kinase inhibitor, with docetaxel in patients with solid tumors.
Graff JN; Higano CS; Hahn NM; Taylor MH; Zhang B; Zhou X; Venkatakrishnan K; Leonard EJ; Sarantopoulos J
Cancer; 2016 Aug; 122(16):2524-33. PubMed ID: 27192055
[TBL] [Abstract][Full Text] [Related]
20. Alisertib: a review of pharmacokinetics, efficacy and toxicity in patients with hematologic malignancies and solid tumors.
Liewer S; Huddleston A
Expert Opin Investig Drugs; 2018 Jan; 27(1):105-112. PubMed ID: 29260599
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
